Top

News & Events

Archive: 2012

News Archive

GE Healthcare and Cellular Dynamics International agree to sublicence for cellular assay patents

Chalfont St. Giles, UK and Madison, WIS, USA – GE Healthcare Life Sciences, a business unit of GE Healthcare (NYSE: GE) and Cellular Dynamics International (CDI), a leading commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, announced today that GE Healthcare has licenced CDI to develop, manufacture and sell cellular assays and models derived from induced pluripotent stem (iPS) cells for use in drug discovery and toxicity screening. The agreement follows the recent announcement that GE Healthcare has expanded its licence with Geron to obtain exclusive global rights to Geron’s intellectual property and know-how for the development and sale of cellular assays derived from iPS cells. Financial terms were not disclosed.

Read more »

e-Therapeutics provides update on progress of ETS2101 cancer trials

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX) today provides an update on the clinical trials of its cancer drug ETS2101. Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively. Interim data from the trials are expected in H1 2013.

Read more »

ZEINCRO Reinforces its Leading Position in Central and South-Eastern Europe

Athens, Greece – ZEINCRO, a specialist provider of clinical research services, announces today that it has reinforced its position in Central and South- Eastern Europe (CSEE), with the opening of offices in 5 additional countries, extending its reach to 14 countries in total.

Read more »

Karus Therapeutics Announces Collaboration with Babraham Institute to Explore PI3 Kinase Inhibitors in the Treatment of Inflammatory Diseases

Southampton, UK – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced that it has entered into a collaboration with the Babraham Institute (Cambridge, UK), to further characterize novel treatments for inflammatory diseases through the regulation of phosphatidylinositol-3-kinase (PI3K) - a family of enzymes important to immune cell function.

Read more »

Pre-transplant Umbilical Cord Blood Expansion in Lab Speeds Establishment of New Blood Supply in Patients, Reducing High-risk Time to Recovery

Houston, Texas, USA – Donated umbilical cord blood establishes a new blood supply in patients more quickly after transplantation when it is first expanded in the lab on a bed of cells that mimics conditions in the bone marrow, researchers report in the Dec. 13 edition of the New England Journal of Medicine.

Read more »

Henri Termeer joins Prosensa as Strategic Advisor

Leiden, The Netherlands – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has appointed industry leader and former Genzyme CEO, Mr. Henri Termeer as Strategic Advisor. His role at Prosensa will be to provide input on the company’s corporate strategy and growth plans.

Read more »

Bicycle Therapeutics announces £3.75 million financing for drug discovery

Cambridge, UK – Bicycle Therapeutics, a next generation biotherapeutics company co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced that it had secured a tranched equity financing of £3.75 million to invest in selection of drug candidates using its bicyclic peptide technology platform. Current investors, Atlas Venture, Novartis Venture Fund, SR One and SV Life Sciences were joined by new investor Astellas Venture Management, the venture capital arm of Astellas Pharma.

Read more »

Two Posters and Two Oral Presentations on NOXXON Compounds at 2012 American Society of Hematology (ASH) Conference

Berlin, Germany - NOXXON Pharma announced its participation at the 54th annual meeting of the American Society of Hematology (ASH) in Atlanta, USA from 8-11 December 2012. Two posters will be presented based on the outcome of two independent Phase I clinical trials which assessed the safety of Spiegelmer NOX H94 in a first-in-human study as well as its potential to prevent an inflammation induced drop in serum iron in a human experimental model of endotoxemia. NOX H94 is a candidate for the treatment of anemia of chronic disease.

Read more »

Sirtex Collaboration with the National Cancer Centre of Singapore

Sydney, Australia – Sirtex Medical Limited (ASX: SRX) announced today that it has signed a Master Research Collaboration Agreement with SingHealth. Under this agreement researchers from Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) will explore the potential of a new technology known as Carbon Cage Nanoparticles to develop a new generation of cancer therapies.

Read more »

NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94

Berlin, Germany – NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease. This Phase IIa study was initiated following the successful completion of the clinical Phase I program, data from which will be presented at the upcoming ASH (American Society of Hematology) meeting in Atlanta, Georgia, 8-11 Dec 2012.

Read more »

Phagenesis Wins Bionow Award for Healthcare Project of the Year 2012

Manchester, UK – Phagenesis Ltd, the global leader in the treatment of dysphagia, has won the Bionow Healthcare Project of the Year 2012 award. The award follows the launch of its first product, Phagenyx™, a medical device that treats dysphagia (difficulty swallowing) after stroke, in October.

Read more »

Mesoblast Corporate Overview

Melbourne, Australia – Mesoblast Limited (ASX: MSB; USOTC: MBLTY) Chief Executive Professor Silviu Itescu today provided shareholders at the company’s 2012 Annual General Meeting with an overview of the company’s corporate strategy, key highlights for the year, and an update on recent progress.

Read more »

FuturaGene and EMBRAPA sign an umbrella Cooperation Framework Agreement

São Paulo, Brazil - FuturaGene, a world leader in the enhancement of yield and sustainability of woody crops for plantation forestry, biopower and biofuel markets, is pleased to announce the signing of a Cooperation Framework Agreement with EMBRAPA, (Empresa Brasileira de Pesquisa Agropecuária) the Brazilian Ministry of Agriculture research organisation. Under the agreement, FuturaGene and EMBRAPA will establish collaborative research programs in eucalyptus and other tree species for the enhancement of sustainable development in Brazil and other territories.  The first project to be executed under the agreement will incorporate an aluminium-tolerance gene of EMBRAPA into FuturaGene eucalyptus germplasm to enhance yields in areas affected by aluminium toxicity in the soil.

Read more »

Apitope Completes Recruitment into its Clinical Trial of ATX-MS-1467 in Multiple Sclerosis

Bristol, UK and Hasselt, Belgium – Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS). Receipt of the first dose of study treatment by the last patient to be recruited prompted an undisclosed clinical milestone payment from Merck Serono, a division of Merck, Germany, with whom Apitope is developing ATX-MS-1467.

Read more »

GE Healthcare’s 2012 Cell Imaging Competition – voting opens to celebrate art, science and discovery

Chalfront St Giles, UK – GE Healthcare Life Sciences, a business unit of GE Healthcare, today announced that voting for the 2012 Cell Imaging Competition is now open at gelifesciences.com/cellimagecompetition.

Read more »

OGT initiates strategic expansion plans in North America with the opening of New York office and appointment of US sales team

Oxford, UK – Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, announced today that it has opened a new office in Tarrytown, New York to support and grow its CytoSure™ cytogenetics arrays and Genefficiency™ next generation sequencing business in the US. 

Read more »

Marinomed Granted Chinese Patent for Antiviral Polymer

Vienna, Austria –  Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, today announced that it has been granted Chinese Patent No. CN101678040, entitled ‘Antiviral polymer’, by the Chinese patent office. The patent covers the use of a specific polymer for the prevention and treatment of rhinovirus infections.

Read more »

Veryan receives CE Mark approval for BioMimics 3D™ Stent

Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), a leading technology commercialisation and investment group, announces that portfolio company Veryan, a vascular disease specialist, has received CE Mark approval for the BioMimics 3D™ Stent.

Read more »

GE Healthcare scientist paired with Cardiff MP to share insights on cell therapy, science and policy-making

Chalfont St. Giles, UK – Dr. Michelle Janas from GE Healthcare Life Sciences recently swapped a lab coat for legislation, when she visited Jenny Willott MP at the House of Commons for a “Week in Westminster” as part of a unique ‘pairing’ scheme run by the Royal Society – the UK’s national academy of science.

Read more »

Source BioScience plc Interim Management Statement

Nottingham, UK − Source BioScience plc, the international diagnostics and genetic analysis business serving the healthcare and research markets today publishes its Interim Management Statement for the period from 1 July 2012 to 14 November 2012.

Read more »

Transformational Events in Healthcare 2012

College Hill Life Sciences and Smith Square Partners, a corporate finance company, co-hosted a dinner for CEOs and executive directors in the healthcare and life sciences sectors.

Read more »

Bacteriophage-based Anti-infective Companies AmpliPhi and Special Phage Services Complete Merger

Richmond, VA, London, UK and Sydney, Australia − AmpliPhi Biosciences Corporation [OTCBB: APHB] (“Ampliphi”) and Special Phage Services (“SPS”) are formally combined following the completion of the share exchange transaction announced on September 10, 2012. Now trading as Ampliphi, the enlarged company combines complementary technologies and expertise in bacteriophage-based therapies to create an exciting development stage pipeline of innovative anti-bacterials addressing the rapidly growing global market treating antibiotic resistant infections.

Read more »

BioGasol ApS raises €15 Million in New Equity and Grant Financing led by Unipension, EUDP and Fjord Capital Partners

Copenhagen, Denmark – BioGasol ApS, the renewable energy company announced today that it has raised €5 million in new equity financing and received a confirmation of €10 million grant allocation from The Energy Technology Development and Demonstration Program (EUDP), part of the Danish Energy Agency.

Read more »

Aravis sells German wind farm to EBM

Zurich, Switzerland - Aravis Energy I LP is a Swiss private equity fund focused on investments in the renewable energy sector, founded in 2008. Aravis has already established various wind and photovoltaic power plants in Germany, Spain and Italy, which currently produce more than 300 million kWh, sufficient to supply energy for around 125,000 local households. Aravis not only invests in operating assets, but also has the experience and local market knowledge to finance and implement new power plants. According to the independent research company Preqin, Aravis Energy I LP is currently the most successful European private equity fund in the renewable energy sector. The German wind farm Frehne I, now owned by Basel-Land’s EBM, is the fourth sale of a facility that has been financed and successfully completed from the fund within the last two years. With an investment volume of about 250 million Swiss francs, Aravis Energy I LP is one of the leading market players in Europe.

Read more »

IXICO and PsiOxus Therapeutics Win Significant Funding from Government-backed Biomedical Catalyst

London, UK − Imperial Innovations Group plc (AIM: IVO, "Innovations", or "the Group), the UK's leading technology commercialisation and investment company, announces that two of its portfolio companies have won significant funding from the government-backed Biomedical Catalyst Awards. IXICO, a leading medical imaging company, and PsiOxus, a development stage biotechnology company developing novel therapeutics for cancer and other clinically unmet diseases, will receive £2.1m and £1.7m respectively to accelerate the translation of scientific ideas into commercial propositions.

Read more »

International Consortium Awarded €6M to Validate Pre-Eclampsia Early Detection Tests

Cork, Ireland and Ghent, Belgium – The European Union has awarded 6 million euro of research funding under the FP7-health framework to a consortium which is working to bring a predictive test for pre-eclampsia to market. The consortium is coordinated by Prof Louise Kenny at University College Cork, Ireland and driven by two companies, Pronota NV of Belgium and Metabolomic Diagnostics Ltd. of Ireland, both at the forefront in the discovery and development of novel blood-borne biomarkers for disease prediction.

Read more »

Forbion Portfolio Company uniQure receives Approval for Glybera® First Gene Therapy by European Commission

Naarden, The Netherlands – Forbion Capital Partners is pleased to announce that its investee company, uniQure received approval today from the European Commission (EC) for the gene therapy Glybera® (alipogene tiparvovec), a treatment for patients with lipoprotein lipase deficiency (LPLD, also called familial hyperchylomicronemia) suffering from recurring acute pancreatitis. Patients with LPLD, a very rare, inherited disease, are unable to metabolize the fat particles carried in their blood, which leads to inflammation of the pancreas (pancreatitis), an extremely serious, painful, and potentially lethal condition. The approval makes Glybera the first gene therapy approved by regulatory authorities in the Western world.

Read more »

Vaxxas Recognized as 2012 Janssen AusBiotech Emerging Company of the Year

Brisbane, Qld, Australia – Vaxxas, a biotechnology company commercializing a novel vaccine-delivery platform that activates immunological cells immediately below the surface of the skin, announced today it has received the 2012 Janssen AusBiotech Emerging Company of the Year Award.  This award recognizes Vaxxas’ significant technological achievements, and efforts to foster growth in the biotechnology industry.

Read more »

College Hill joins Roche and AstraZeneca on Pharma TV

Watch some hints and tips on the value of communications in the biotech industry and in support of pharma deal making.

View feature

Read more »

Celtic Therapeutics Announces the Appointment of New Partner

New York, USA and Lausanne, Switzerland – Celtic Therapeutics L.L.L.P., the global private equity firm focused on novel therapeutic product candidates, today announced that Beth P. Hecht has joined the company as a Partner and Chief Legal and Administrative Officer.  Most recently, Ms. Hecht was Senior Vice President, General Counsel and Secretary of The Sun Products Corporation of Wilton, Connecticut.

Read more »

Pharma Television

The importance of communications in Life Sciences, October 2012 - [00:05:45]

Read more »

Agenix to Acquire Diagnostic Device Technology from Tyrian Limited

Melbourne, Australia -- 25 October 2012 -- Agenix Limited (ASX: AGX) today announced it had entered an agreement with Tyrian Diagnostics Limited (ASX: TDX) to license its rapid point-of-care human diagnostic technology in a share exchange transaction. Under the terms of the agreement, Agenix will license exclusive world-wide royalty free rights to the human health application for Tyrian’s proprietary DiagnostIQ® rapid point-of-care test platform. In return, Agenix will provide Tyrian with Agenix shares to the value of $0.5million payable in installments to be completed by June 2014.

Read more »

miReven announces positive preclinical results for miR-7 in head and neck cancer

Perth, Western Australia – MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7, today announced the publication in the journal PLOS One of a study in which miR-7 was examined in combination with the head and neck cancer (HNC) treatment erlotinib hydrochloride (Tarceva, Genentech/OSIP).

Read more »

Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy

Leiden, The Netherlands – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.

Read more »

Scil Proteins Obtains EMA Approval for Commercial Production of Reteplase

Halle,Germany − Scil Proteins Production GmbH, a private biotech company specializing in the research, development and production of recombinant proteins, announced today that the European Medicines Agency (EMA) has approved Scil Proteins’ Halle facilities for manufacturing of Reteplase, marketed by Actavis as Rapilysin®.

Read more »

Ampliphi presents encouraging pre-clinical data on the use of phage-based therapies to treat bacterial lung infections

Richmond, VA, USA and Colworth, UK − AmpliPhi Biosciences Corporation presented encouraging data from a pre-clinical animal model study of acute infection with Pseudomonas aeruginosa at the 26th Annual North America Cystic Fibrosis Foundation Conference held 11-13 October in Florida, USA (NACFC). The data generated in collaboration with scientists at Institut Pasteur in Paris and using AmpliPhi’s phage discovery platform show that the company’s proprietary mix of bacteriophage is able to clear lung infection with efficacy comparable or superior to a high dose of an antibiotic shown to be effective against the infecting bacteria in the laboratory.

Read more »

College Hill Life Sciences Welcomes a Prestigious Roster of New Clients

London, Manchester, Munich, Boston, Sydney, Melbourne: Underlining its 20 percent plus growth in revenues during 2012, and its international expansion, College Hill Life Sciences is pleased to have attracted a prestigious roster of new companies to its client base. New clients range from start-ups to multi-nationals, both for fully retained services and for branding and PR projects.

Read more »

Phagenesis wins CE mark for Phagenyx™ to treat dysphagia

Manchester, UK – Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that its treatment system Phagenyx™, the world's first treatment for acute dysphagia following stroke, has been awarded a CE Mark. 

Read more »

BD and Lab21 Collaborate to Develop New Oncology Assays on the BD MAX™ Platform

Baltimore, MD and Cambridge, UK –  BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Lab21, a global leader in personalized healthcare diagnostics, announced today that they will collaborate to develop oncology assays for the BD MAX™ fully automated, bench-top molecular system.

Read more »

Australia’s Benitec Biopharma acquires US-based Tacere Therapeutics Inc and its Phase I/II ready hepatitis C (HCV) program

Sydney, Australia and San Jose, California, USA – Australian-based Benitec Biopharma (ASX: BLT) today announced the execution of an agreement to acquire the US-based RNA interference (RNAi) therapeutics company Tacere Therapeutics, Inc. (Tacere). 

Read more »

Data from Phase I/IIa study of Verona Pharma’s dual PDE 3 and 4 inhibitor RPL554 demonstrated safety and efficacy in healthy subjects and asthmatics

London, UK – Verona Pharma plc (AIM: VRP.L), the drug discovery and development company with first-in-class drugs to treat respiratory diseases, today presents data  at the International Severe Asthma Forum in Gothenburg demonstrating that the novel inhaled medicine RPL554 is well tolerated and produces a pronounced bronchodilator response in subjects with asthma.

Read more »

BAC and GE Healthcare collaboration wins industry award

Naarden, The Netherlands – BAC BV, the leading provider of antibody-based affinity purification technology, announced today that a successful long-term collaboration with GE Healthcare, the healthcare business of GE (NYSE: GE), to develop innovative purification media for the production of novel types of biopharmaceuticals has been recognised with the “Collaboration of the Decade Award -Downstream Processing” at the BioProcess International Awards 2012.

Read more »

LEUKOCARE licenses biomarker cell-free DNA to Trillium Diagnostics

Munich, Germany, and Bangor, Maine, USA - LEUKOCARE AG, a German biotech company, and Trillium Diagnostics, LLC, an US-based diagnostic company, announced today that both partners have formed a strategic alliance regarding the development and marketing of LEUKOCARE’s patented method for the detection of inflammatory activity using the novel biomarker circulating cell-free DNA (cf-DNA). Trillium will use the technology to develop a commercial assay for the diagnosis of sepsis.

Read more »

Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

Cambridge, MA, USA – Vaxxas, a biotechnology company commercializing a novel vaccine delivery platform, today announced the initiation of a research collaboration with Merck, known as MSD outside the United States and Canada. The collaboration will evaluate Vaxxas’ proprietary Nanopatch™ platform that induces robust immune system activation by targeting vaccine to the abundant immunological cells immediately below the surface of the skin.  In addition, Vaxxas has granted Merck an exclusive license for the Nanopatch platform for commercial production of an undisclosed vaccine candidate.

Read more »

Clinigen Group plc - Admission to AIM and fund raising

College Hill supported Clinigen Group plc in its Admission to AIM on the London Stock Exchange – the first IPO in the pharma/biotech sector on AIM in five years. The team provided strategic financial PR advice, media training, prepared materials and implemented the PR campaign around the Intention to Float, Pricing announcements and design of Prospectus.

Visit Clinigen website

Read more »

Circassia Initiates Phase III Trial for Cat Allergy Treatment

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘Innovations’, or ‘the Group’), a leading technology commercialisation and investment company, announces that its portfolio company, Circassia has initiated a pivotal large-scale phase III clinical study of its ToleroMune® cat allergy treatment.

Read more »

College Hill Life Sciences Announces Two Promotions to Partner

London, Manchester: The Life Sciences team of College Hill, the International business communications consultancy, within the College Group, has announced the promotion of Melanie Toyne-Sewell and Chris Fisher to Partner.

Read more »

College Hill Life Sciences’ London Team Celebrates Three Promotions

London: The Life Sciences team of College Hill, the International business communications consultancy within the College Group, has announced the promotion is delighted to announce the promotion of three members of its London team: Dr Anastasios “Tasos” Koutsos, Dr Rebecca “Bex” Caygill and Henry Stanley. Tasos moves up to the position of Junior Account Director, Bex to Junior Account Manager and Henry to Account Executive.

Read more »

Brooks Life Science Systems Launch the Plate Auditor™ for Automated Compound Quality Control

Poway, CA, USA – Brooks Life Science Systems, a division of Brooks Automation, Inc. (Nasdaq: BRKS), a leading worldwide provider of automation solutions for compound and biological sample storage and management, today announced the commercial launch of the Brooks Plate Auditor™, a fast, accurate and non-invasive tool for identification of precipitate and empty wells in compound and screening plates. The new Plate Auditor is the result of a successful collaboration with the Scripps Research Institute.

Read more »

Multiplicom Launches New Genomic and Somatic Mutation Detection Kits

Niel, Belgium Multiplicom, a molecular diagnostics company specializing in innovative molecular genetics tests based on massively parallel sequencing (MPS) today announces that it is launching new genomic and somatic mutation detection kits based on its proprietary MASTR technology.

Read more »

Prosensa Named a Fierce 15 Biotech Company

Leiden, the Netherlands – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has been named by FierceBiotech as one of 2012’s Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.

Read more »

Media training – practice makes perfect

Following the successful workshop on social media in the life sciences held in Melbourne in May 2012, Sue Charles and Douglas Pretsell were again on stage sharing their experience of effective media management during a half day training session organised by AusBiotech, Australia’s biotech trade association.

Read more »

Verona Pharma: Interim Report for the Six Months Ended 30 June 2012

London, UK − Verona Pharma plc (AIM: VRP.L), is a drug development company with first-in-class drugs to treat respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and chronic, severe cough. Today, the Company announces its unaudited interim results for the six months ended 30 June 2012.

Read more »

FuturaGene appoints Dr. Michael May, VP Public Affairs

São Paulo, Brazil − FuturaGene, a world leader in the enhancement of yield and sustainability of woody crops for plantation forestry, biopower and biofuel markets, has appointed Dr Michael May, Ph.D. as VP Public Affairs. He was previously a Public Policy Consultant at FuturaGene.

Read more »

College Hill Life Sciences on stage in Oxford

The Life Sciences team is a core sponsor of the Oxford Spin-out Equity Management (OSEM) which runs a series of events every year.  OSEM manages Oxford University's shareholdings in its spin-out companies and seeks ways of maximising the value of its equity stakes. The group has been holding networking and learning events for its portfolio companies and investors in the Oxford area.

Read more »

Brooks’ Single-Use REMP Tubes Support Optimization of Automated Serum and Plasma storage

Poway, CA, USA - Brooks Life Science Systems, a division of Brooks Automation, Inc. (Nasdaq: BRKS), a leading worldwide provider of automation solutions for compound and biological sample storage and management, announced today that Karolinska Institute Biobank (KI Biobank) is successfully using Brooks’ REMP single-use heat sealed sample tubes to secure the long-term storage of plasma, serum and urine samples in its automated biorepositories.

Read more »

e-Therapeutics Starts Second Phase I Cancer Trial of ETS2101

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX) announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James’s University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle. It complements an investigator-led phase I study of ETS2101 in brain cancer that began in San Diego, California during June.

Read more »

Three College Hill Life Sciences' Clients Shortlisted for 2012 SCRIP Industry Awards

London: College Hill Life Sciences clients' are well represented in the list of finalists for the 2012 Scrip awards, with Mesoblast, Prosensa and Roche and all making it to the shortlist, following the nomination entries prepared and submitted by College Hill.

Read more »

AmpliPhi to Combine with Special Phage Services to Create World's Leading Anti-infective Company Focused on Bacteriophage-based Therapies

Richmond, VA, London, UK and Sydney, NSW, Australia − AmpliPhi Biosciences Corporation [APHB.PK] (“AmpliPhi”), today announced that it has offered to acquire Brookvale, Sydney-based Special Phage Services (“SPS”). The combination of the two companies would result in the creation of a leading anti-infective company focused on developing phage-based therapies to combat the growing threat of antibiotic-resistant infection.

Read more »

Forbion Announces Appointment of Philip Astley-Sparke as Venture Partner

Naarden, The Netherlands, Munich, Germany and Boston, USA − Forbion Capital Partners today announced Philip Astley-Sparke, the former President and CEO of BioVex, has joined the investment team as a venture partner based in Boston, USA. He will work with selected Forbion’s portfolio companies as a board member and/or advisor to help management to execute on their business plans.

Read more »

Karus Therapeutics Secures Series B Financing from a Syndicate of Leading VC Investors

Southampton, UK – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, announces the closing of its Series B investment, which includes a first tranche of $7.6 million. The financing was led by new investors, SV Life Sciences, New Leaf Ventures, Novo A/S and International Biotechnology Trust, who were joined by existing investors, IP Group and a number of Angel investors.

Read more »

OGT Forms Scientific Advisory Board

Oxford, UK - Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, announced today the formation of a Scientific Advisory Board chaired by Peter Rigby, Emeritus Professor of Developmental Biology at the Institute of Cancer Research and Deputy Chairman of the Board of Governors at the Wellcome Trust.

Read more »

GE Healthcare launches modular biopharmaceutical factory, KUBio

Chalfont St Giles, UK – GE Healthcare, the healthcare business of GE (NYSE: GE), today introduced KUBio™, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money.  KUBio’s pre-made modules, which are assembled at a customer’s chosen site to make a fully functional ready-to-run bioprocessing facility, are significantly faster to install than constructing a traditional factory. The modules are equipped with GE Healthcare’s world-class technologies for the start-to-finish manufacture of biopharmaceuticals.

Read more »

Verona Pharma Reports Bronchodilator Data with RPL554 in COPD Patients at the 2012 European Respiratory Society

London, UK - Verona Pharma plc (AIM: VRP.L), the drug discovery and development company with first-in-class drugs to treat respiratory diseases, today announces the completion and reporting of data from a clinical trial with its lead drug candidate, the dual PDE 3 and 4 inhibitor RPL554, in patients with chronic obstructive pulmonary disease (COPD).  The data was presented by the trial’s Principal Investigator, Professor Mario Cazzola, at the European Respiratory Society (ERS) Annual Congress in Vienna.

Read more »

New Data on RPL554 in COPD to be Presented at ERS Annual Congress

London, UK –Verona Pharma plc (AIM: VRP.L), the drug discovery and development company with first-in-class drugs to treat respiratory diseases, announces that new data on the Company’s lead compound RPL554 will be presented at this year’s European Respiratory Society (ERS) Annual Congress in Vienna.

Read more »

Brooks Life Science Systems Announces New Applications for Celigo® Imaging Cytometer

Poway, CA, USA − Brooks Life Science Systems, a division of Brooks Automation, Inc. (Nasdaq: BRKS), today announced that its ongoing investment and development of the Celigo® Imaging Cytometer is bringing new capabilities to academic research, biopharmaceutical drug development and high-throughput and high-content screening.

Read more »

US Patent Granted for Verona Pharma’s RPL554

London, UK – Verona Pharma plc (AIM: VRP.L), the drug discovery company with first-in-class drugs to treat respiratory diseases, today announces that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554. The patent is the fourth patent issued for RPL554 and related compounds in the US.

Read more »

Mireven Receives Further $500K from MRCF

Perth, Western Australia – MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7, today announced that it had received a further AU$500K investment from the Medical Research Commercialisation Fund (MRCF) due to the successful completion of various technical and commercial milestones. This brings the total that the MRCF has invested in MiReven since its foundation in 2010 to AU$1.1M.

Read more »

GE Healthcare launches ÄKTA™ pure, a new modular chromatography system for protein purification

Chalfont St Giles, UK – GE Healthcare, the healthcare business of GE (NYSE: GE) announced today the launch of ÄKTA™ pure, a chromatography system for flexible, reliable and intuitive purification of proteins.  ÄKTA pure, the latest addition to the industry-leading ÄKTA range of chromatography systems, is an easy-to-use modular system that offers the flexibility to support both routine and challenging purification requirements, as well as being adaptable to changing research needs.   

Read more »

EBM and ewb Take Over 70-Megawatt Wind Farms

Münchenstein/Bern/Zürich, Switzerland − The two utility companies EBM and Energie Wasser Bern (ewb) continue to expand their share of energy production from renewable sources. Through their joint venture company "leading swiss renewables AG" and with the support of Aravis they acquired a Spanish wind energy company which subsequently took over two wind farms with a total capacity of 70 megawatts (MW).

 

Read more »

Allergan and Molecular Partners Enter into Exclusive Alliance

Irvine, California, USA / Zurich-Schlieren, Switzerland − 21 August, 2012 −  Allergan, Inc. (NYSE: AGN) and Molecular Partners AG today announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin® products for the treatment of serious ophthalmic diseases.
 

Read more »

Source Bioscience: Half Year Report for the Six Months Ended 30 June 2012

Source BioScience plc (LSE: SBS) the international diagnostics and genetic analysis business, announces its Half Year Report for the six months ended 30 June 2012.

Read more »

College Hill Life Sciences Supporting BioPartnering FutureEUROPE

London, UK and Brussels, Belgium – College Hill invites you to BioPartnering FutureEUROPE™ 2012.  BioPartnering FutureEUROPE™ is an evolution of BioPartnering Europe (BPE), the life science industry’s longest-running partnering event, celebrating its 20th year.  This year’s event will be held in Brussels, with subsequent annual events taking place in Stockholm and other European capitals.

Read more »

College Group Acquires Merlin Financial Communications

College Group has acquired Merlin Financial Communications, a leading London based Financial PR consultancy which will be integrated into our College Hill Capital Markets practice.

This acquisition is very much in line with the delivery of the Group’s ambitious growth strategy of building an international business communications consultancy which meets the increasing requirements of its clients. The Group now acts for over 650 clients globally, including over 10 Fortune 500 corporations.

Read more »

FuturaGene Launches Field Trials in China

Sao Paulo, Shanghai – FuturaGene, a world leader in the enhancement of yield and sustainability of woody crops for plantation forestry, biopower and biofuel markets, has launched four field trials for selection and improvement of plant species in Gansu province, in northwestern China. The trials will evaluate the potential of woody crops and certain shrub varieties to combat desertification, enable soil regeneration and produce economic offtake for biopower and liquid biofuels.

Read more »

GE Healthcare launches FF High Performance nitrocellulose membranes optimized for diagnostic assay reproducibility

GE Healthcare Life Sciences’ new WhatmanTM FF High Performance (HP) membrane provides the industry with a new diagnostic membrane to enable fast, razor-sharp line separation and highly reproducible results for the detection of target molecules in liquids such as water, urine, blood and saliva. The target molecules may include drugs, hormones, proteins, antibodies, nucleic acids, whole bacteria and viruses.

Read more »

NICE Publishes Positive Diagnostics Guidance on DySIS Cervical Cancer Screening Product

Edinburgh, UK - DySIS Medical Ltd, the medical devices company in female health, announces that the National Institute for Health and Clinical Excellence (‘NICE’) has today published positive diagnostics guidance recommending its DySIS cervical cancer screening product to be considered in procurement plans.

Read more »

FuturaGene Head of R&D Appointed Extraordinary Professor for Forestry and Agricultural Biotechnology

Shanghai – FuturaGene, a world leader in the enhancement of yield and sustainability of woody crops for plantation forestry, biopower and biofuel markets, announced today that its Head of R&D in China, Prof. David (Xudong) Zhou has been appointed as an Extraordinary Professor at the Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, South Africa. This appointment further strengthens the relationship between FuturaGene and FABI.

Read more »

iBio, Inc. and GE Healthcare Form New Global Alliance

Newark, DE, USA and Chalfont St Giles, UK – iBio, Inc. (NYSE MKT: IBIO), and GE Healthcare, the healthcare business of GE (NYSE: GE), announced today a new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines.  The alliance builds on the existing development and marketing agreement between the two companies announced in 2010 and combines iBio’s innovative plant-based vaccine manufacturing platform, iBioLaunch™, with GE Healthcare’s world-class capabilities in start-to-finish technologies for biopharmaceutical manufacturing. iBio’s research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB) will continue to play a key role in advancing the iBioLaunch platform.  Financial terms were not disclosed. 

Read more »

OGT Awarded €3 Million from Prestigious EU Clinical Research Grants

Oxford, UK – Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, announced today that its next generation sequencing service team has been awarded two EU- funded clinical research grants worth €3 million.  OGT will be providing genomic analysis and commercialisation services for two key international studies, EUCLIDS and PATHSEEK.

Read more »

Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis

Melbourne, Australia − Regenerative medicine company Mesoblast Limited (ASX:MSB) today announced positive results in a large animal model of Rheumatoid Arthritis (RA) following a single intravenous injection of its proprietary allogeneic, or “off-the-shelf”, immunomodulatory adult Mesenchymal Precursor Cells (MPCs). 

Read more »

Trading Update for the Six Months Ended 30 June 2012

Nottingham, UK – Source BioScience plc (LSE: SBS), the international diagnostic and genetic analysis business serving the healthcare and research markets, announces the following trading update ahead of its results for the six months ended 30 June 2012.

Read more »

Boehringer Ingelheim and Funxional Therapeutics Announce Acquisition of Funxional’s FX125L and the Somatotaxin Portfolio to Treat Inflammation

Ingelheim, Germany and Cambridge, UK – Today, Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics’ FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed. 

Read more »

Innovations Invests in £17 Million Funding Round for Portfolio Company, Cell Medica

London, UK Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), a leading technology commercialisation and investment group, has invested in a £17 million funding round in portfolio company Cell Medica, a clinical stage cell therapeutics business, enabling it to continue development of its immune reconstitution cell therapies in Europe and to launch new operations in Texas, US, focussing on cancer immunotherapy. Invesco Perpetual and the Cancer Prevention and Research Institute of Texas (CPRIT) also participated in the round.

Read more »

Forbion Portfolio Company, uniQure Receives Positive Opinion for Glybera® in Europe from CHMP

Naarden, The Netherlands − Forbion Capital Partners is pleased to announce, that its investee company uniQure has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) that recommends marketing authorization of Glybera® (alipogene tiparvovec) as a treatment for lipoprotein lipase deficiency (LPLD) under exceptional circumstances. LPLD is a very rare, inherited disease. Patients with the disease are unable to handle fat particles in their blood plasma, which leads to recurring severe abdominal pain and pancreatitis.

Read more »

College Hill Ranked 14th Largest UK Healthcare Consultancy by PR Week

London: International business communications consultancy College Hill is pleased to have been ranked 14th in this year’s PR Week’s league table of the top 25 UK healthcare consultancies, based on 2011 gross revenues for healthcare PR work undertaken by College Hill’s Life Sciences team. Income generated by the life sciences team represents a 15% increase in College Hill’s healthcare revenues over 2010.

Read more »

ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D

Lausanne, Switzerland – ADC Therapeutics (ADCT), the drug development company targeting cancers with antibody-drug conjugate (ADC) “warhead” therapies, today announced the appointment of former Genmab Vice President Dr Patrick van Berkel as Senior Vice President, Research & Development.

Read more »

Lab21 Among First to Offer FDA Approved Companion Diagnostic in the US

Cambridge, UK – Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics is pleased to announce that its CLIA laboratory in Greenville, South Carolina, has been named as one of nine laboratories in the US to offer the first FDA approved companion diagnostic test to provide guidance for the use of Erbitux® (cetuximab).

Read more »

NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX A12 for Treatment of Chronic Lymphocytic Leukemia

Berlin, Germany – NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer. CXCL12 signaling has been shown to play an important role in the pathophysiology of CLL, especially in the interaction of leukemic cells with the tissue microenvironment. The therapeutic concept of NOX-A12 is to inhibit such tumor-supporting interactions and thereby sensitize CLL cells to chemotherapy.

Read more »

Clydesdale Bank £5 million funding to support Lab21 international growth

Cambridge, UK – Clydesdale Bank has provided a new £5 million package for Lab21, the global specialist in personalised medicine and clinical diagnostics.

Read more »

Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-term Pre-eclampsia Cases in SCOPE Consortium Study

Ghent, Belgium – Pronota NV, a company dedicated to the development of best-in-class diagnostics for early detection of life-threatening conditions, announced today that it has successfully validated its mid-gestation pre-eclampsia screening test. This test correctly identifies 80% of women at risk for the development of pre-term pre-eclampsia according to a study in collaboration with the SCreening fOr Pregnancy Endpoints (SCOPE) Consortium, one of the largest international research efforts dedicated to the prediction of late pregnancy diseases.

Read more »

Verona Pharma Initiates Dosing in Clinical Trial to Investigate Anti-inflammatory Properties of RPL554

London, UK – Verona Pharma plc (AIM: VRP.L), the biotechnology company focused on developing novel treatments for chronic respiratory diseases, today announces that it has commenced a new trial with its lead drug candidate, the dual PDE 3 and 4 inhibitor, RPL554.

Read more »

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

London, UK and Lausanne, Switzerland – Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT)* announce today that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries.

Read more »

LEUKOCARE Provides Key Technologies for Tumour Diagnosis in Personalized Medicine Research Project Multi-National Consortium Receives €6 Million EU Grant

Munich, Germany – LEUKOCARE AG, a privately-owned company providing technologies for protein stabilization and biological surface coating, announced today that it will receive funding from the EU FP7 grant programme to participate in a four-year international research project aimed at developing a new blood apheresis device for in vivo trapping of circulating tumour cells.

Read more »

Source BioScience Launches New Illumina MiSeq™ Next Generation DNA Sequencing Service

Nottingham, UK – Source BioScience plc (LSE: SBS), the European leader in DNA sequencing and genomic services, announces the launch of an extended next generation sequencing service using the new Illumina MiSeq™ technology platform.

Read more »

Bioxyne reports the results from the Phase IIb study

Sydney, Australia – Australian immunotherapeutics business, Bioxyne Limited (ASX: BXN), has received the preliminary analysis of the study 005 which examines the efficacy and safety of the immunotherapeutic, HI 164 OV in patients with chronic obstructive pulmonary disease (COPD).

Read more »

Celtic Pharma: Data from New Drug Trial Offers Prospect for Enhanced Quality of Life for Children with Late Stage Brain Tumors

Bermuda, London and New York – Data presented today by Dr. Stewart Goldman M.D of the Children’s Memorial Hospital, Chicago at the International Symposium for Pediatric Neuro-Oncology being held in Toronto, Canada showed encouraging positive results from a Phase I/II study of Xerecept in Pediatric Patients with Peritumoral Cerebral Edema (brain tumors).

Read more »

ProtAffin AG starts Phase 1 study for lead product PA401 in inflammatory lung disease

Graz, Austria and London, UK – ProtAffin AG, a biotechnology company developing a novel class of next-generation biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has started dosing healthy volunteers in a Phase 1 clinical study in the UK with its novel investigational anti-inflammatory product, PA401.

Read more »

Imperial Innovations Group plc – Abingdon Health acquires controlling stake in Forsite Diagnostics

London, UK  – Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), a leading technology commercialisation and investment group, announces that its portfolio company Abingdon Health (‘Abingdon’) has made an investment and acquired a controlling 80% interest in Forsite Diagnostics (‘Forsite’), a private UK-based contract developer and manufacturer of lateral flow diagnostic products.

Read more »

Lab21 partners with major pharmaceutical company to develop new companion diagnostic assay

Cambridge, UK – Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with one of the world’s leading pharmaceutical companies to develop, manufacture and distribute a  new companion diagnostic assay for the detection of specific mutations in colorectal cancer samples to select patients for the partner’s therapeutic monoclonal antibody.

Read more »

College Hill Congratulates The BioCentury Team for Winning "Mediscience Commentator of the Year" Award

London: College Hill Life Sciences is delighted to congratulate the team from BioCentury for winning the 2012 award for the "Mediscience Commentator of the Year " at the European Mediscience Awards on 21st June 2012 in recognition of the BioCentury publication’s clear and concise commentary on the Life Sciences sector.

Read more »

Astex Pharmaceuticals Announces Initiation of the Phase 2 Expansion of the SGI-110 clinical trial in MDS and AML Patients

DUBLIN, Calif. – Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated the Phase 2 dose expansion segment of the clinical trial of SGI-110, a novel hypomethylating agent, in patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).  Treatment-naive MDS and elderly AML (≥65 years) will be enrolled in the dose expansion.

Read more »

Prosensa wins “Emerging Star Award” at the European Mediscience Awards

Leiden, The Netherlands – Prosensa, the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, has won the Emerging Star accolade at last night’s European Mediscience Awards.

Read more »

College Hill Life Sciences Welcomes Three New Hires to its London and Manchester Teams

London, Manchester: International business communications consultancy College Hill announces the appointment of three new additions to its Life Sciences team. Jen Lewis joins the Manchester office as an Account Manager, while Dr Rebecca Caygill and Henry Stanley join the London office as Junior Account Executives.

Read more »

Multiplicom’s BRCA MASTR™ Dx test accredited with CE/IVD mark

Niel, Belgium – Multiplicom, a molecular diagnostics company specializing in innovative molecular genetics tests based on massive parallel sequencing, has received CE/IVD mark accreditation for its first-in-class BRCA MASTR Dx test. The test identifies mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers.

Read more »

NOXXON Initiates Phase IIa of anti-CCL2/MCP-1 Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy

Berlin, Germany – NOXXON Pharma today announced the treatment of the first patient in a Phase IIa clinical trial of its anti-CCL2/MCP-1 (C-C Chemokine Ligand 2 or Monocyte Chemoattractant Protein-1) Spiegelmer NOX-E36 in patients with diabetic nephropathy. About 1 in 3 patients with diabetes mellitus develops diabetic nephropathy, a progressive kidney disease that is one of the main causes of end-stage renal disease and the need for dialysis. The recruitment of immune cells by the chemokine CCL2 into the kidney along with direct effects of CCL2 on cells of the kidney are believed to be important in the progression of this disease.

Read more »

Imperial Innovations Group plc – Innovations leads $28m funding round for Oxford Immunotec

London, UK – Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), a leading technology commercialisation and investment group, has led a $28m funding round for Oxford Immunotec, alongside Invesco Perpetual and existing investors.

Read more »

PolyTherics granted further patents for TheraPEG™ and GlycoPol™

London, UK – PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, has strengthened its intellectual property estate with the granting of further patents for TheraPEG™, its site-specific conjugation technology, in Australia and Japan; and for GlycoPol™, a glycopolymer for targeted delivery of biotherapeutics, in the US.

Read more »

OncoEthix In-Licenses OTX015, an anticancer Bromodomain inhibitor from Mitsubishi Tanabe Pharma Corporation

Lausanne, Switzerland – OncoEthix, a Swiss-based company specializing in oncology drug development, has in-licensed a compound, OTX015, from Mitsubishi Tanabe Pharma Corporation (MTPC).

Read more »

Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial Initiation of a FGFR Kinase Inhibitor

DUBLIN, Calif. – Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that Janssen Pharmaceutica NV has received clearance to commence a Phase I clinical trial of a Fibroblast Growth Factor Receptor (FGFR) kinase inhibitor from its collaborative, cancer drug discovery program with Astex.  The regulatory approval required to take the compound into Phase I triggers a milestone payment to Astex of £3.5 million (US$5.4 million).  Astex is also eligible to receive further milestones during clinical development and royalties on commercialization of products derived from the collaboration.

Read more »

Annual General Meeting Statement

Laurie Turnbull, Chairman of Source BioScience, will be making comments at the 2012 Annual General Meeting to be held on the 13th June at 10.30am.

Read more »

BGI, GE Healthcare team up on pioneering stem cell science projects

Chalfont St. Giles, UK, and Shenzhen, China – GE Healthcare, the healthcare business of GE (NYSE: GE), and BGI, the world’s largest genomics organization, jointly announced today a pioneering multi-year research collaboration in stem cell science. The objective of the collaboration is to help advance the potential global utility of stem cell-derived assays for use in drug discovery and toxicity testing by exploring the underlying genetic variation between ethnically diverse human stem cell lines. The collaboration was announced at a signing ceremony attended by Dr Amr Abid, General Manager Cell Technologies, GE Healthcare Life Sciences and Lin Fang, Vice President of BGI, Ye Yin, Deputy President of BGI, and Yutao Du, Deputy President of BGI.

Read more »

Polyphor signs MacroFinder® collaboration with Boehringer Ingelheim

Allschwil, Switzerland – Polyphor Ltd today announced the signing of a research collaboration and license agreement with Boehringer Ingelheim, under which Polyphor will apply its proprietary MacroFinder® drug discovery technology to identify and optimize novel macrocyclic drug candidates addressing therapeutic targets selected by Boehringer Ingelheim. In return, Polyphor will receive from Boehringer Ingelheim an up-front payment, research funding and milestone payments as candidate molecules progress through the drug discovery process, preclinical and clinical development and onto the market. In addition, Polyphor is eligible for undisclosed royalties on the commercial sales of any approved products.

Read more »

BioInvent and Cancer Research Technology enter Oncology collaboration

Lund, Sweden and London, UK – BioInvent International AB (OMXS: BINV) and Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK, announced today that they have entered a collaboration with Queen Mary, University of London, to identify new therapeutic antibodies in oncology.

Read more »

Trial Masters joins ZEINCRO to create specialist CRO in Central- and South-Eastern Europe

Athens, Greece and Budapest, Hungary – ZEINCRO, a specialist provider of clinical research services in Greece, Turkey and Cyprus, today announced it is consolidating with Trial Masters Ltd, a contract research organisation managing clinical trials in Hungary and Romania.

Read more »

Microtest Diagnostics appoints senior industry executive Kjell Kristiansen as Group Managing Director

London, UK – Microtest Diagnostics, a diagnostic company with an in-vitro allergy and autoimmunity testing platform called ADAM™ designed for use directly by doctors and allergy specialists, today announces that it has appointed former Phadia AB senior executive, Kjell Kristiansen as Group Managing Director.

Read more »

Mesoblast Provides Corporate Strategy For Product Development To Treat Neurologic Conditions

Melbourne, Australia – Mesoblast Limited (ASX:MSB) today outlined the Company’s strategic plans to develop adult stem cell therapies for neurodegenerative diseases at the Jefferies Global Healthcare Conference in New York.

Read more »

Multiplicom receives €200,000 grant for novel non-invasive pre-natal test

Niel, Belgium – Multiplicom, a molecular diagnostics company specializing in the design, development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing, announces that it has been awarded a €200,000 ($260,000) grant from the Flemish agency for Innovation by Science and Technology (IWT). The grant is intended to support the development of a novel test for genetic abnormalities during pregnancy that needs only a blood sample, in contrast to the invasive screening methods in use today. The test will be based on Multiplicom’s proprietary MASTR (Multiplex Amplification of Specific Targets for Resequencing) workflow.

Read more »

College Hill Launches New Office in Melbourne, Australia

London, Sydney, Melbourne: On the back of its success in emerging business growth in Australia, College Hill, the international business communications consultancy within the College Group is pleased to announce the opening of its new office in Melbourne. The office will be headed by Senior Consultant, Dr Douglas Pretsell, who moved to Melbourne in February this year, and is co-located within the offices of the Medical Research Commercialisation Fund and College Hill client and leading Australian life science venture investor, Brandon Capital, at 278 Collins Street in the very heart of Melbourne’s Central Business District.

Read more »

Forest Laboratories and Nabriva Therapeutics Sign Agreement

Vienna, Austria – Forest Laboratories and Nabriva Therapeutics announced today they have entered into an agreement for the development of Nabriva’s novel antibacterial agent, BC-3781.  Pursuant to the agreement, Forest will provide Nabriva with $25 million, and fund and conduct in collaboration with Nabriva, certain development activities related to BC-3781 over the next 12 months.  During the 12-month period, Forest has the exclusive right to acquire Nabriva.  Forest's decision to acquire Nabriva will be dependent upon certain contingencies.  No further financial or other terms were disclosed.  The transaction is subject to customary regulatory clearances including termination of the applicable Hart-Scott-Rodino waiting period. Citi and WilmerHale acted as advisors to Nabriva in regards to this transaction.

Read more »

CEO’s Statement to Annual General Meeting

At the Annual General Meeting of Verona Pharma being held today, the Company's Chief Executive Officer, Professor Michael Walker, will make the following statement:

“Verona Pharma has experienced ...

Read more »

Molecular Partners AG strengthens management team with the appointment of Lisa Rojkjaer, MD as Chief Medical Officer

Zurich-Schlieren, Switzerland – Molecular Partners AG, the leader in the discovery and development of DARPins®, a novel class of therapeutic proteins, today announced the appointment of Lisa Rojkjaer, MD as Chief Medical Officer, strengthening the existing management team.

Read more »

Pro Bono Bio and PolyTherics progress and expand their relationship for the development of improved blood factors

London, UK – Pro Bono Bio Group plc (“PBB”), the international healthcare group, and PolyTherics Limited (“PolyTherics”), a provider of solutions for the development of better biopharmaceuticals, announce progress on their haematology alliance to produce longer-acting versions of blood factor proteins.  The lead programme, for the development of TheraPEG™ Factor IX, has shown good technical and scientific progress and the parties have extended their agreement to actively pursue the development of a further blood factor product, TheraPEG™ Factor VIIa.  In addition, encouraged by the results achieved with these two programmes they have embarked on a feasibility study to assess the potential of a TheraPEG™ Factor VIII product.

Read more »

Bioxyne On Track To Report Clinical Trial Results In June

Sydney, Australia – Bioxyne Limited (ASX: BXN), today confirmed it is on track for the release of data from its Phase IIb trial as scheduled in June.
The Company confirmed the 320-patient study to evaluate the efficacy and safety of the Bioxyne’s HI-164OV therapy for patients with chronic obstructive pulmonary disease (COPD) had been closed and that data was in the late stages of analysis.

Read more »

College Hill Life Sciences Adds New Talent to its Munich Team

Munich: The Life Sciences team of international business communications consultancy College Hill has announced the appointment of Dr Adriane Lochner as Account Executive based in its Munich office.

Read more »

Promotions Awarded to Three Members of College Hill Life Sciences’ London Team

London: International business communications consultancy College Hill has announced the promotion of three members of its Life Sciences team in London. Jayne Crook, Gemma Howe and Dr Anastasios “Tasos” Koutsos. Gemma becomes an Account Manager, while Jayne and Tasos both move up to the position of Senior Account Manager.

Read more »

College Hill Supports e-Therapeutics’ Facility Opening in Oxford by the British Prime Minister

London: The Life Sciences team of international business communications consultancy, College Hill was pleased to have supported its drug discovery and development client e-Therapeutics plc (ETX:LSE), in the organisation of the Company’s opening ceremony for its new Oxford facility. The new facility was officially opened by the British Prime Minister Rt Hon David Cameron MP on 24 February 2012.

Read more »

College Hill Expands its Team in Australia

London, Sydney, Melbourne: On the back of its success in growing business in Australia, College Hill – the international business communications consultancy – has announced that Dr Douglas Pretsell, Associate Partner in the Life Sciences team will move to Australia in February to establish a presence in Melbourne, Victoria, one of the largest hubs for the life sciences industry in Australia and home of its national association, Ausbiotech.

Read more »

College Hill Strengthens Life Sciences Team with Appointment of Christelle Kerouedan

London, Manchester, Munich, Sydney, Boston, Atlanta: The Life Sciences team of international business communications consultancy, College Hill has announced the appointment of Dr Christelle Kerouedan to the newly created post of Projects Director in the London office. Christelle will take responsibility for the management of design, copywriting and other client projects, as well as support the Life Sciences team in operational management and marketing. Christelle also extends the team’s European language capabilities and will provide support for any French language outreach.

Read more »

College Hill Wins Global PR Account with NASDAQ-listed Astex Pharmaceuticals

London, Manchester, Munich, Sydney, Boston, Atlanta: The Life Sciences team of international business communications consultancy, College Hill has announced that it has won the global mandate to support Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) in its corporate communications.

Read more »

Dr Robert Mayer Takes the Helm in Germany as General Manager of the Life Science Munich Office

London, Manchester, Munich, Sydney, Boston: The Life Sciences team of international business communications consultancy, College Hill has announced that Dr Robert Mayer steps up to the role of General Manager of the Munich office, leading the team in Germany. This is effective from 1st of January 2012.

Read more »

College Hill Reaffirms Association with European Mediscience Awards 2012

London: The European Mediscience Awards, the event which celebrates the best in the quoted life sciences, healthcare and biotech industries is delighted to announce that long-term supporters, College Hill have confirmed its association with the 2012 event, joining headline sponsor Nomura Code and Netherlands-based merchant bank, Kempen & Co. The event will mark the 11th annual European Mediscience Awards and will be held on Thursday 21 June 2012 at the Hotel InterContinental in London.

Read more »